2025-11-16T14:44:18-06:00 2024-12-31 911194016 CLARK NUBER PS 555 110TH AVE NE SUITE 700 BELLEVUE WA 98004 990 2024-01-01 352577906 MAXAID MAXA 4257788660 1416 NW 46TH STREET SUITE 105 146 SEATTLE WA 98107 EDGAR THOMAS CFO 4257788660 2025-11-14 1 0 FRANCES OLSON P01228048 4254544919 2025-11-14 2024 2025-03-06 01:10:19Z PATRICIA GARCIA-GONZALEZ 1416 NW 46TH STREET SUITE 105 146 SEATTLE WA 98107 309119754 0 X WWW.MAXAID.ORG X 2016 WA MAXAID IS A 501(C)(3) NON-PROFIT SUBSIDIARY OF THE MAX FOUNDATION, SUPPORTING ITS MISSION TO ACCELERATE HEALTH EQUITY BY DELIVERING MEDICATION, TECHNOLOGY, AND SERVICES TO PATIENTS FACING CANCER AND OTHER CRITICAL ILLNESSES, FOCUSING OUR ENERGY ON THOSE NO ONE ELSE IS HELPING. 8 7 0 31 0 0 311110506 309073442 0 0 0 46312 0 0 311110506 309119754 288941066 363316002 0 0 0 0 0 0 0 6233415 7699219 295174481 371015221 15936025 -61895467 136816838 73562738 1501014 142381 135315824 73420357 THE PRIMARY PURPOSE OF MAXAID IS TO CARRY OUT TREATMENT ACCESS SOLUTIONS FOR ONCOLOGY AND OTHER CRITICAL ILLNESS PRODUCTS IN LOW AND MIDDLE INCOME COUNTRIES IN SUPPORT OF THE MAX FOUNDATION'S MISSION. 0 0 371008697 363316002 MAXAID HOSTS THE MAX FOUNDATION'S COLLABORATION WITH LEADING GLOBAL HEALTHCARE MANUFACTURERS, FOR HUMANITARIAN ACCESS TO CRITICAL MEDICINES UNDER THE UMBRELLA OF MAX ACCESS SOLUTIONS. WITHIN THIS PROGRAM, MEDICINES ARE PROCURED FROM DRUG MANUFACTURERS ANDCHANNELED TO INDIVIDUAL PATIENTS THROUGH THE MAX FOUNDATION'S NETWORK OF HEALTHCARE PROVIDERS AND TREATMENT CENTERS. THE COLLABORATIONS ENABLE THOUSANDS OF PATIENTS IN LOW- AND MIDDLE-INCOME COUNTRIES TO ACCESS MUCH NEEDED ONCOLOGY PRODUCTS THAT THEY WOULD NOT HAVE OTHERWISE BEEN ABLE TO ACCESS. ACCESS TO MEDICINES WAS ENABLED THROUGH THE MAX FOUNDATION'S PATIENT-CENTERED TREATMENT ACCESS MODEL CALLED MAX ACCESS SOLUTIONS. 371008697 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 1 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 X 8 7 0 0 0 0 0 0 0 1 0 0 0 1 1 1 1 1 1 0 0 0 X X LISSA KENDALL 4257788660 1416 NW 46TH STREET SUITE 105 146 SEATTLE WA 98107 PATRICIA GARCIA-GONZALEZ CHIEF EXECUTIVE OFFICER 5.00 50.00 X X 0 322386 26903 PAULA BOULTBEE BOARD CHAIR 2.00 5.00 X X 0 0 0 CURT MALLOY BOARD TREASURER 2.00 5.00 X X 0 0 0 JERALD JERRY RADICH MD BOARD MEMBER 2.00 5.00 X 0 0 0 SUSAN JERIAN BOARD MEMBER 2.00 5.00 X 0 0 0 MABEL WOLOJ BOARD SECRETARY 2.00 5.00 X X 0 0 0 EDGAR THOMAS BOARD MEMBER 2.00 5.00 X 0 0 0 MARIA PIA RUFFILLI BOARD MEMBER 2.00 5.00 X 0 0 0 JOHN MENAPACE CFO & VP, ADMINISTRATION 2.00 40.00 X 0 209319 18740 0 531705 45643 0 0 1 0 THE MAX FOUNDATION 1416 NW 46TH STREET SUITE 105 UNI SEATTLE WA 98107 PROFESSIONAL SERVICES 7691197 TANNER PHARMA CH GMBH ALTE STEINHAUSERSTRASSE 21 CHAM SZ 6330 SUPPLY CHAIN MANAGEMENT 4057955 TANNERGAP INC 1808 ASSOCIATES LANE STE A CHARLOTTE NC 28217 SUPPLY CHAIN MANAGEMENT 507307 3 309073442 297857284 309073442 46312 46312 309119754 0 0 46312 363316002 363316002 6460 6460 7691197 7691197 64 64 TAXES AND LICENSES 1498 1498 371015221 371008697 6524 0 2978034 1123728 3010000 2380000 130527544 69745945 301260 313065 136816838 73562738 70503 139351 1430511 3030 1501014 142381 X 584113 308579 134731711 73111778 135315824 73420357 136816838 73562738 -61895467 0 X 0 1 X 1 0 X X X 1 THE MAX FOUNDATION 911893957 7 1 7691197 363316002 1 7691197 363316002 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 PART I, LINE 12G (VI) MAXAID SUPPORTS THE EFFORTS OF THE MAX FOUNDATION THROUGH BOTH CASH AND NON-CASH CONTRIBUTIONS. DURING THE TAX YEAR, MAXAID MADE $7,691,197 IN CASH GRANTS, AND $363,316,002 OF NONCASH ASSISTANCE IN THE FORM OF CANCER TREATMENT DRUGS TO BENEFIT THE CHARITABLE CLASS. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 DUE TO MAX FOUNDATION 3030 3030 1 SOUTH ASIA 0 0 GRANTS TO RECIPIENTS IN REGION 144177000 SUB-SAHARAN AFRICA 0 0 GRANTS TO RECIPIENTS IN REGION 103089000 RUSSIA AND NEIGHBORING STATES 0 0 GRANTS TO RECIPIENTS IN REGION 53518000 CENTRAL AMERICA AND THE CARIBBEAN 0 0 GRANTS TO RECIPIENTS IN REGION 21520000 SOUTH AMERICA 0 0 GRANTS TO RECIPIENTS IN REGION 16339000 EAST ASIA AND THE PACIFIC 0 0 GRANTS TO RECIPIENTS IN REGION 14248000 NORTH AMERICA 0 0 GRANTS TO RECIPIENTS IN REGION 4980000 MIDDLE EAST AND NORTH AFRICA 0 0 GRANTS TO RECIPIENTS IN REGION 547000 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTS TO RECIPIENTS IN REGION 221000 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 PROGRAM EXPENSES CANCER TREATMENT DRUGS 4158000 SOUTH AMERICA 0 0 PROGRAM EXPENSES CANCER TREATMENT DRUGS 35000 SOUTH ASIA 0 0 PROGRAM EXPENSES CANCER TREATMENT DRUGS 3000 CENTRAL AMERICA AND THE CARIBBEAN 0 0 PROGRAM EXPENSES CANCER TREATMENT DRUGS 3000 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 FUNDRAISING 0 0 0 0 0 0 358418000 4420000 362838000 DRUG CENTRAL AMERICA AND THE CARIBBEAN 2243 0 21520468 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG EAST ASIA & THE PACIFIC 1485 0 14247835 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG EUROPE (INCLUDING ICELAND & GREENLAND) 23 0 220674 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG MIDDLE EAST AND NORTH AFRICA 57 0 546887 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG NORTH AMERICA 519 0 4979546 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG RUSSIA AND NEIGHBORING STATES 5578 0 53518131 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG SOUTH AMERICA 1703 0 16339437 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG SOUTH ASIA 15027 0 144176579 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG SUB-SAHARAN AFRICA 10744 0 103089328 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE 1 0 0 0 0 0 PART I, LINE 2: ALL GRANTS TO FOREIGN ENTITIES OR INDIVIDUALS ARE MADE SUBJECT TO A WRITTEN AGREEMENT OR AWARD LETTER THAT CLEARLY DEFINES DELIVERABLES. THE MAX FOUNDATION MAINTAINS A PROGRAM DATABASE IN ORDER TO TRACK DOCUMENTATION OF GRANT REQUESTS, QUALIFIED GRANTEES, AND FULFILLMENT OF GRANT REQUESTS. PROGRAM STAFF MEMBERS MONITOR THE EXECUTION OF GRANT DELIVERABLES TO ENSURE THAT THE TERMS OF THE AGREEMENT ARE FULFILLED ON A TIMELY BASIS. PART I, LINE 3: THE EXPENDITURES REPORTED ON SCHEDULE F, PART I ARE ON THE ACCRUAL BASIS OF ACCOUNTING. PART IV, LINE 1 FORM 926 IS NOT REQUIRED TO BE FILED BECAUSE THE TRANSFER TO A FOREIGN COPORATION DOES NOT MEET THE REPORTING REQUIREMENTS IN IRC SEC. 6038(A)(1)(A). 0 0 0 0 0 0 0 0 0 PATRICIA GARCIA-GONZALEZ CHIEF EXECUTIVE OFFICER 0 280589 0 41797 0 0 0 9672 0 17231 0 349289 0 0 JOHN MENAPACE CFO & VP, ADMINISTRATION 0 209319 0 0 0 0 0 6280 0 12460 0 228059 0 0 PART I, LINE 3 NO REVIEW OF COMPENSATION WAS REQUIRED SINCE NO OFFICERS WERE PAID BY THIS ORGANIZATION. A RELATED AND SUPPORTED ORGANIZATION, THE MAX FOUNDATION, PERFORMS THE ANNUAL REVIEW PROCESS FOR THESE INDIVIDUALS AS APPLICABLE. A WRITTEN CONTRACT AND BOARD APPROVAL ARE USED. X 29784882 297857284 HIGHEST COMM. VOL. 1 0 1 0 PART I, COLUMN (B): THE NUMBER IN COLUMN B REPRESENTS THE NUMBER OF TABS CONTRIBUTED. FORM 990, PART I, LINE 6, VOLUNTEERS: THERE ARE EIGHT VOLUNTEER BOARD MEMBERS AND TWENTY-THREE VOLUNTEER ADVISORY BOARD MEMBERS. FORM 990, PART VI, SECTION A, LINE 8B COMMITTEE OVERSIGHT IS PROVIDED BY THE MAX FOUNDATION UNDER A SERVICES AGREEMENT BETWEEN THE TWO ORGANIZATIONS. FORM 990, PART VI, SECTION B, LINE 11B THE TAX RETURN IS PREPARED BY AN OUTSIDE ACCOUNTANT. AFTER PREPARATION, THE FINANCE COMMITTEE PERFORMS A REVIEW OF THE RETURN. THE RETURN IS THEN FILED WITH THE IRS. A COPY IS PROVIDED TO THE BOARD OF DIRECTORS PRIOR TO FILING WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C THE BOARD HAS ADOPTED A CONFLICT OF INTEREST POLICY AND THE POLICY IS REVIEWED ON AN ANNUAL BASIS. EACH YEAR, BOARD MEMBERS AND OFFICERS MUST REVIEW THE POLICY AND DETERMINE IF ANY CONFLICT OF INTERESTS EXIST. ANNUALLY, THE DISCLOSURES WERE REVIEWED BY THE EXECUTIVE ASSISTANT. SHOULD A CONFLICT ARISE, IT WOULD BE REVIEWED BY THE CFO, CEO AND BOARD TREASURER OF THE RELATED ORGANIZATION, MAX FOUNDATION. NO BOARD MEMBER OR OFFICER MAY VOTE ON ANY MATTER UNDER CONSIDERATION IN WHICH SUCH PERSON HAS A CONFLICT OF INTEREST. FURTHER, ANY PERSON WITH A MATERIAL CONFLICT OF INTEREST IN ANY DECISION SHOULD BE ABSENT FROM THE ROOM DURING THE BOARD'S REVIEW, INCLUDING ITS VOTE, ON THE DECISION IN QUESTION. FORM 990, PART VI, SECTION B, LINE 15 NO REVIEW OF COMPENSATION WAS REQUIRED SINCE NO OFFICERS WERE PAID BY THIS ORGANIZATION. A RELATED AND SUPPORTED ORGANIZATION, THE MAX FOUNDATION, PERFORMS THE ANNUAL REVIEW PROCESS FOR THESE INDIVIDUALS AS APPLICABLE. FORM 990, PART VI, SECTION C, LINE 19 THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE PROVIDED UPON REQUEST. THE MAX FOUNDATION 1416 NW 46TH STREET SUITE 105 UNIT SEATTLE WA 98107 911893957 EXPAND HUMANITARIAN ACCESS TO TREATMENTS FOR CANCER WA 501(C)(3) LINE 10 0 THE MAX FOUNDATION SOUTH AFRICA TRUST 10 COSMOSPLACE DOORNPOORT PRETORIA SF TO SUPPORT THE MAX FOUNDATION SF MAX FOUNDATION T 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0